Russian vaccine data add to expectations for COVID-19 vaccine efficacy set by BioNTech, Pfizer; Moderna readout coming

The first interim Phase III readout for Sputnik V suggests the Russian COVID-19 vaccine and BNT162b2 from BioNTech and Pfizer have similar efficacies as an interim analysis that will reveal whether Moderna and NIH’s mRNA-1273 stacks up is imminent.

Antibody countermeasures are also progressing, with Vir gearing up to begin Phase III trials of its lead antiviral mAb in new treatment settings and to bring its second candidate into the clinic; and SPARK Global developing nasal drops for temporary immunity. ...